|
The Brand's Latest Multi-Tasking Leave-In Treatment Delivers Stronger, Healthier-Looking Hair
VENTURA, Calif., March 3, 2026 /PRNewswire/ -- RevitaLash® Cosmetics, the internationally recognized leader in lash, brow, and hair care, announces the exciting launch of its new Leave-In Hair Mask & Conditioner; a breakthrough 5-in-1 restorative treatment that delivers deep hydration, protection, and strength without weighing hair down.
This innovative, multi-purpose formula delivers the nourishing, smoothing, and hydrating benefits of a traditional hair mask, with no rinse, no heavy residue, and no extra time required. Suitable for all hair types and color-safe, the lightweight leave-in treatment is ideal for those experiencing dry, dull, flat, or fragile hair, and is especially beneficial for thinning or damaged strands seeking renewed vitality and shine.
Powered by a nutrient-rich blend of ingredients, Leave-In Hair Mask & Conditioner primes, nourishes, and protects hair from environmental aggressors and heat styling (lab testing showed heat protection up to 450°F/232°C*) while supporting stronger, more resilient strands. A nourishing blend of Tamanu, Coconut, Avocado, Jojoba, and Moringa Oils, along with Trehalose, Hydrolyzed Hyaluronic Acid, and Amaranth Peptides, deeply hydrates, smooths, and improves manageability.
"We're excited to expand our hair care portfolio with a multi-benefit product capable of replacing the need to buy – and use – four additional products at a time when consumers are craving simplicity, and stretching their dollars. The fact that it also delivers professional-level results is the icing on top," said Lori Jacobus, President and Global CMO of RevitaLash® Cosmetics. "Our new Leave-In Hair Mask & Conditioner gives consumers the deep care benefits of a mask with the convenience of a lightweight leave-in, making it easier than ever to support stronger, shinier, more resilient hair every day."
Designed to complement the brand's Volumizing Hair Collection, the Leave-In Hair Mask & Conditioner integrates seamlessly into daily routines. After cleansing and conditioning, users simply apply a dime-sized amount to damp, towel-dried hair from mid-lengths through ends, then brush and style as usual.
The formula is dermatologist reviewed, clinically tested, hypoallergenic, vegan-friendly, cruelty-free, and free from parabens, phthalates, and gluten. It is proudly made in the U.S.A.
RevitaLash® Cosmetics Leave-In Hair Mask & Conditioner (90 mL / 3.0 fl oz) retails for $42.50 and will be available through authorized salons, spas, specialty retailers, and on revitalash.com beginning March 1st.
About RevitaLash® Cosmetics
RevitaLash® Cosmetics is a worldwide leader in developing advanced lash, brow and hair beautification products. Established in 2006, the collection includes award-winning RevitaLash® Advanced Eyelash Conditioner and RevitaBrow® Advanced Eyebrow Conditioner, and is available in physician's offices, spas, salons, and specialty retailers across 70+ countries. A supporter of non-profit breast cancer initiatives, RevitaLash® Cosmetics donates a portion of proceeds to research and education initiatives, giving back to the breast cancer community year-round, not just in October. For information, visit www.revitalash.com.
*Results from a controlled lab study using Leave-In Hair Mask & Conditioner vs. shampooed hair. Keratin denaturation measured over 4 applications of heat.
The Brand's Latest Multi-Tasking Leave-In Treatment Delivers Stronger, Healthier-Looking Hair
VENTURA, Calif., March 3, 2026 /PRNewswire/ -- RevitaLash® Cosmetics, the internationally recognized leader in lash, brow, and hair care, announces the exciting launch of its new Leave-In Hair Mask & Conditioner; a breakthrough 5-in-1 restorative treatment that delivers deep hydration, protection, and strength without weighing hair down.
This innovative, multi-purpose formula delivers the nourishing, smoothing, and hydrating benefits of a traditional hair mask, with no rinse, no heavy residue, and no extra time required. Suitable for all hair types and color-safe, the lightweight leave-in treatment is ideal for those experiencing dry, dull, flat, or fragile hair, and is especially beneficial for thinning or damaged strands seeking renewed vitality and shine.
Powered by a nutrient-rich blend of ingredients, Leave-In Hair Mask & Conditioner primes, nourishes, and protects hair from environmental aggressors and heat styling (lab testing showed heat protection up to 450°F/232°C*) while supporting stronger, more resilient strands. A nourishing blend of Tamanu, Coconut, Avocado, Jojoba, and Moringa Oils, along with Trehalose, Hydrolyzed Hyaluronic Acid, and Amaranth Peptides, deeply hydrates, smooths, and improves manageability.
"We're excited to expand our hair care portfolio with a multi-benefit product capable of replacing the need to buy – and use – four additional products at a time when consumers are craving simplicity, and stretching their dollars. The fact that it also delivers professional-level results is the icing on top," said Lori Jacobus, President and Global CMO of RevitaLash® Cosmetics. "Our new Leave-In Hair Mask & Conditioner gives consumers the deep care benefits of a mask with the convenience of a lightweight leave-in, making it easier than ever to support stronger, shinier, more resilient hair every day."
Designed to complement the brand's Volumizing Hair Collection, the Leave-In Hair Mask & Conditioner integrates seamlessly into daily routines. After cleansing and conditioning, users simply apply a dime-sized amount to damp, towel-dried hair from mid-lengths through ends, then brush and style as usual.
The formula is dermatologist reviewed, clinically tested, hypoallergenic, vegan-friendly, cruelty-free, and free from parabens, phthalates, and gluten. It is proudly made in the U.S.A.
RevitaLash® Cosmetics Leave-In Hair Mask & Conditioner (90 mL / 3.0 fl oz) retails for $42.50 and will be available through authorized salons, spas, specialty retailers, and on revitalash.com beginning March 1st.
About RevitaLash® Cosmetics
RevitaLash® Cosmetics is a worldwide leader in developing advanced lash, brow and hair beautification products. Established in 2006, the collection includes award-winning RevitaLash® Advanced Eyelash Conditioner and RevitaBrow® Advanced Eyebrow Conditioner, and is available in physician's offices, spas, salons, and specialty retailers across 70+ countries. A supporter of non-profit breast cancer initiatives, RevitaLash® Cosmetics donates a portion of proceeds to research and education initiatives, giving back to the breast cancer community year-round, not just in October. For information, visit www.revitalash.com.
*Results from a controlled lab study using Leave-In Hair Mask & Conditioner vs. shampooed hair. Keratin denaturation measured over 4 applications of heat.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
RevitaLash® Cosmetics Launches 5-in-1 Leave-In Hair Mask & Conditioner
|
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
HiRO's Founder and CEO, Dr. Karen Chu, was a featured speaker at RESI JPM, where she moderated a panel convening investors and strategics at the forefront of the cell and gene therapy revolution. Panelists Robert Balfour of ALSA Ventures and Bettina Ernst of BERNINA BioInvest highlighted the current momentum in cell and gene therapies, discussed how they assess technical and commercial risk, identified partnership models that accelerate progress, and outlined where capital is flowing in this rapidly advancing field.
Dr. Chu also led a workshop titled "Leveraging Asia: How to Navigate Asian VC Investment Mandates." The session opened with the 2026 industry outlook and key trends, then highlighted priority therapeutic areas. It explained the NewCo model and the criteria Asian venture capital firms use to evaluate global biotech assets, their co‑investment preferences, and expectations for commercialization. The workshop featured Asia‑based investors Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group; Jayson Lee, Partner and Head of Healthcare Investing, LongRiver Investments; and Dr. Maomeng Tong, Principal, INCE Capital, who shared strategic insights for biotechs pursuing cross‑border capital or collaboration.
"Asia's steady capital recovery is fueling more diverse, higher-quality biotech deals. Investors are increasingly favoring more scalable, capital-efficient, innovative business models. One such emerging approach is the NewCo model, which combines equity participation with experienced management teams, leverages Asia's efficient clinical speed and ecosystem partners to accelerate data generation, and enables program-level co-development. These elements de-risk global development in multiple ways, making the opportunities more attractive for international syndicates," said Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group.
"Clinical development now spans multiple regions more than ever and requires an integrated strategy. HiRO's cross‑border capabilities across APAC, the US, and Europe allow us to align regulatory strategy, site selection, and operational execution to bridge data across regions, accelerate timelines, and reduce redundant costs. By leveraging local expertise, regional cost advantages, and selective partnerships, we help biotech sponsors generate earlier, higher‑quality readouts and deploy capital more efficiently to advance financing and licensing goals," said Dr. Karen Chu, Founder and CEO of HiRO.
About Harvest Integrated Research Organization (HiRO)
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization. With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
HiRO's Founder and CEO, Dr. Karen Chu, was a featured speaker at RESI JPM, where she moderated a panel convening investors and strategics at the forefront of the cell and gene therapy revolution. Panelists Robert Balfour of ALSA Ventures and Bettina Ernst of BERNINA BioInvest highlighted the current momentum in cell and gene therapies, discussed how they assess technical and commercial risk, identified partnership models that accelerate progress, and outlined where capital is flowing in this rapidly advancing field.
Dr. Chu also led a workshop titled "Leveraging Asia: How to Navigate Asian VC Investment Mandates." The session opened with the 2026 industry outlook and key trends, then highlighted priority therapeutic areas. It explained the NewCo model and the criteria Asian venture capital firms use to evaluate global biotech assets, their co‑investment preferences, and expectations for commercialization. The workshop featured Asia‑based investors Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group; Jayson Lee, Partner and Head of Healthcare Investing, LongRiver Investments; and Dr. Maomeng Tong, Principal, INCE Capital, who shared strategic insights for biotechs pursuing cross‑border capital or collaboration.
"Asia's steady capital recovery is fueling more diverse, higher-quality biotech deals. Investors are increasingly favoring more scalable, capital-efficient, innovative business models. One such emerging approach is the NewCo model, which combines equity participation with experienced management teams, leverages Asia's efficient clinical speed and ecosystem partners to accelerate data generation, and enables program-level co-development. These elements de-risk global development in multiple ways, making the opportunities more attractive for international syndicates," said Dr. Alva Chen, Managing Director and Head of Therapeutics, VMS Group.
"Clinical development now spans multiple regions more than ever and requires an integrated strategy. HiRO's cross‑border capabilities across APAC, the US, and Europe allow us to align regulatory strategy, site selection, and operational execution to bridge data across regions, accelerate timelines, and reduce redundant costs. By leveraging local expertise, regional cost advantages, and selective partnerships, we help biotech sponsors generate earlier, higher‑quality readouts and deploy capital more efficiently to advance financing and licensing goals," said Dr. Karen Chu, Founder and CEO of HiRO.
About Harvest Integrated Research Organization (HiRO)
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization. With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
